Tumor-associated glycoantigen, sialyl Lewisa as a target for bispecific antibody-directed adoptive tumor immunotherapy
- 1 January 1995
- journal article
- Published by Elsevier in Immunology Letters
- Vol. 44 (1) , 35-40
- https://doi.org/10.1016/0165-2478(94)00177-s
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- School of Medicine, Tokai University
This publication has 11 references indexed in Scilit:
- Specific targeting of in vitro‐activated human antitumour effector cells using anti‐CD3 × anti‐c‐erbB‐2 bispecific antibodyImmunology & Cell Biology, 1993
- Response to the letter from Drs Gold and OsbandBritish Journal of Cancer, 1993
- Large-scale culture system of human CD4+ helper/killer T cells for the application to adoptive tumour immunotherapyBritish Journal of Cancer, 1992
- Human C‐ERBB‐2 proto‐oncogene product as a target for bispecific‐antibody‐directed adoptive tumor immunotherapyInternational Journal of Cancer, 1992
- Bispecific antibodies and targeted cellular cytotoxicityImmunology Today, 1991
- Immunotheraphy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2Immunology Letters, 1990
- Preliminary trial of specific targeting therapy against malignant gliomaThe Lancet, 1990
- Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor responseCell, 1990
- In vivo generation of lymphokine-activated killer cells by sensitization with interleukin 2-producing syngeneic T-lymphoma cellsCellular Immunology, 1988
- Colorectal carcinoma antigens detected by hybridoma antibodiesSomatic Cell and Molecular Genetics, 1979